Eledon Pharmaceuticals, Inc. Operating Cash Flow
Eledon Pharmaceuticals, Inc. (ELDN) reported Operating Cash Flow of -$45.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Eledon Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$22.68M.
- Eledon Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$22.61M.
- Eledon Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$14.09M.
- Eledon Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$14.48M.
- Eledon Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$62.34M.
- Eledon Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$47.27M.
- Eledon Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$39.53M.
- Eledon Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$28.42M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$45.29M 10-Q · filed 2026-08-13 | -$59.38M derived: sum of 3 quarters · filed 2026-08-13 | -$73.86M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$22.61M 10-Q · filed 2026-05-13 | -$36.70M derived: sum of 2 quarters · filed 2026-05-13 | -$51.18M derived: sum of 3 quarters · filed 2026-05-13 | -$68.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$14.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$28.57M derived: sum of 2 quarters · filed 2026-03-19 | -$46.28M derived: sum of 3 quarters · filed 2026-08-13 | -$62.34M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$14.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$32.19M derived: sum of 2 quarters · filed 2026-08-13 | -$48.25M 10-Q · filed 2025-11-14 | -$67.24M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$17.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$33.77M 10-Q · filed 2026-08-13 | -$52.76M derived: sum of 3 quarters · filed 2026-08-13 | -$64.53M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$16.06M 10-Q · filed 2026-05-13 | -$35.05M derived: sum of 2 quarters · filed 2026-05-13 | -$46.82M derived: sum of 3 quarters · filed 2026-05-13 | -$54.59M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$18.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$30.76M derived: sum of 2 quarters · filed 2026-03-19 | -$38.53M derived: sum of 3 quarters · filed 2026-03-19 | -$47.27M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$11.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$19.54M derived: sum of 2 quarters · filed 2025-11-14 | -$28.28M 10-Q · filed 2025-11-14 | -$37.41M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$7.77M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2025-08-14 | -$16.52M 10-Q · filed 2025-08-14 | -$25.65M derived: sum of 3 quarters · filed 2025-08-14 | -$37.90M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$8.74M 10-Q/A · filed 2025-08-14 | -$17.87M derived: sum of 2 quarters · filed 2025-08-14 | -$30.12M derived: sum of 3 quarters · filed 2025-08-14 | -$38.34M derived: sum of 4 quarters · filed 2025-08-14 |
| 2023-12-31 | -$9.13M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-08-14 | -$21.38M derived: sum of 2 quarters · filed 2025-08-14 | -$29.60M derived: sum of 3 quarters · filed 2025-08-14 | -$39.53M 10-K/A · filed 2025-08-14 |
| 2023-09-30 | -$12.25M derived: 10-Q 9 month − 10-K/A 6 month · filed 2024-11-12 | -$20.47M derived: sum of 2 quarters · filed 2024-11-12 | -$30.40M 10-Q · filed 2024-11-12 | -$39.88M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$8.22M derived: 10-K/A 6 month − 10-Q/A 3 month · filed 2024-08-19 | -$18.14M 10-K/A · filed 2024-08-19 | -$27.63M derived: sum of 3 quarters · filed 2024-08-19 | -$32.20M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | -$9.92M 10-Q/A · filed 2024-08-19 | -$19.40M derived: sum of 2 quarters · filed 2024-08-19 | -$23.98M derived: sum of 3 quarters · filed 2024-08-19 | -$30.19M derived: sum of 4 quarters · filed 2024-08-19 |
| 2022-12-31 | -$9.48M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-19 | -$14.05M derived: sum of 2 quarters · filed 2024-08-19 | -$20.27M derived: sum of 3 quarters · filed 2024-08-19 | -$28.42M 10-K/A · filed 2024-08-19 |
| 2022-09-30 | -$4.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$10.79M derived: sum of 2 quarters · filed 2023-11-09 | -$18.94M 10-Q · filed 2023-11-09 | -$28.15M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$6.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$14.37M 10-Q · filed 2023-08-10 | -$23.58M derived: sum of 3 quarters · filed 2023-08-10 | -$30.67M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$8.16M 10-Q · filed 2023-05-11 | -$17.36M derived: sum of 2 quarters · filed 2023-05-11 | -$24.46M derived: sum of 3 quarters · filed 2023-05-11 | -$31.90M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$16.30M derived: sum of 2 quarters · filed 2023-03-30 | -$23.75M derived: sum of 3 quarters · filed 2023-03-30 | -$28.91M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$7.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$14.54M derived: sum of 2 quarters · filed 2022-11-14 | -$19.70M 10-Q · filed 2022-11-14 | -$29.14M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$7.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$12.61M 10-Q · filed 2022-08-11 | -$22.05M derived: sum of 3 quarters · filed 2022-08-11 | -$22.61M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$5.17M 10-Q · filed 2022-05-12 | -$14.60M derived: sum of 2 quarters · filed 2022-05-12 | -$15.16M derived: sum of 3 quarters · filed 2022-05-12 | -$18.18M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$9.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$9.99M derived: sum of 2 quarters · filed 2022-03-24 | -$13.02M derived: sum of 3 quarters · filed 2022-03-24 | -$15.21M 10-K · filed 2022-03-24 |
| 2020-09-30 | -$561.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$3.58M derived: sum of 2 quarters · filed 2021-11-12 | -$5.78M 10-Q · filed 2021-11-12 | -$7.80M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$3.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$5.22M 10-Q · filed 2021-08-12 | -$7.24M derived: sum of 3 quarters · filed 2021-08-12 | -$10.13M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$2.20M 10-Q · filed 2021-05-14 | -$4.22M derived: sum of 2 quarters · filed 2021-05-14 | -$7.11M derived: sum of 3 quarters · filed 2021-05-14 | -$12.03M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | -$2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$4.91M derived: sum of 2 quarters · filed 2021-03-31 | -$9.83M derived: sum of 3 quarters · filed 2021-03-31 | -$13.86M 10-K · filed 2021-03-31 |
| 2019-09-30 | -$2.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$7.81M derived: sum of 2 quarters · filed 2020-11-16 | -$11.83M 10-Q · filed 2020-11-16 | -$15.19M derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | -$4.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$8.95M 10-Q · filed 2020-08-14 | -$12.30M derived: sum of 3 quarters · filed 2020-08-14 | -$15.23M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | -$4.02M 10-Q · filed 2020-05-15 | -$7.38M derived: sum of 2 quarters · filed 2020-05-15 | -$10.31M derived: sum of 3 quarters · filed 2020-05-15 | -$13.64M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | -$3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-17 | -$6.29M derived: sum of 2 quarters · filed 2020-03-17 | -$9.62M derived: sum of 3 quarters · filed 2020-03-17 | -$11.89M 10-K · filed 2020-03-17 |
| 2018-09-30 | -$2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | -$6.27M derived: sum of 2 quarters · filed 2019-11-13 | -$8.54M 10-Q · filed 2019-11-13 | -$11.15M derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-06-30 | -$3.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$5.61M 10-Q · filed 2019-08-13 | -$8.22M derived: sum of 3 quarters · filed 2019-08-13 | -$11.63M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | -$2.27M 10-Q · filed 2019-05-14 | -$4.88M derived: sum of 2 quarters · filed 2019-05-14 | -$8.30M derived: sum of 3 quarters · filed 2019-05-14 | |
| 2017-12-31 | -$2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | -$6.03M derived: sum of 2 quarters · filed 2019-03-28 | -$14.94M 10-K · filed 2019-03-28 | |
| 2017-09-30 | -$3.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$12.33M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | -$8.91M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |